<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03578133</url>
  </required_header>
  <id_info>
    <org_study_id>OXTREC 19-18</org_study_id>
    <nct_id>NCT03578133</nct_id>
  </id_info>
  <brief_title>Causes of Pneumonia in Yangon</brief_title>
  <official_title>A Cross-sectional Study Investigating the Causes of Pneumonia in Two Community Clinics in Two Yangon Townships, Myanmar</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myanmar Oxford Clinical Research Unit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Action Myanmar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Medical Research, Myanmar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Myanmar Oxford Clinical Research Unit</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate a new point of care diagnostic test for the diagnosis of melioidosis
      pneumonia in patients attending outpatient clinics in Yangon, Myanmar
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melioidosis is caused by Burkholderia pseudomallei, a Gram-negative saprophytic environmental
      bacterium that is an important emerging tropical infection. There are an estimated 165,000
      cases and 89,000 deaths world-wide each year. Eighty-four percent of cases are in SE Asia
      where mortality is 40%; far exceeding most recognised neglected tropical diseases. Pneumonia,
      secondary to either inhalation of B.pseudomallei or to bacteraemic spread to the lung is the
      commonest presentation (51%). Annually the highest burden (75%) of infection occurs in the
      rainy season in (75% in Thailand). Up to 80% patients have at least one recognised risk
      factor for melioidosis including; diabetes, alcohol-dependence, glucocorticoid therapy,
      chronic obstructive pulmonary disease (COPD), chronic renal disease and cancer. COPD and
      diabetes mellitus are amongst the top ten causes of death in Myanmar (2018). Patients with
      HIV have not been shown to have greater risk of B. pseudomallei than immunocompetent
      patients.

      Melioidosis was discovered in Myanmar in 1911 by British pathologist Alfred Whitmore and his
      assistant CS Krishnaswami. Yet since 1949 there have been few published cases.
      Under-reporting is partly due to difficulty in diagnosing melioidosis. Clinical and
      radiological findings are indistinguishable from tuberculosis. Laboratory diagnosis is
      challenging, lack of facilities, expertise and awareness of B.pseudomallei results in missed
      diagnostic opportunities.

      Culture is the gold-standard diagnostic method but requires appropriate facilities and
      expertise which are not readily available in many developing countries like Myanmar. A rapid
      diagnostic (RDT) test has been developed for low resource settings that has been evaluated in
      Laos and India. The InBios® Active Melioidosis DetectTM-Lateral Flow Assay (AMD-LFA) detects
      B.pseudomallei 6-deoxyheptan capsular polysaccharide antigen. Shaw et al demonstrated
      sensitivity 85.71% (CI:74.61% to 93.25%) and specificity 93.62% (CI:88.23% to 97.04%), with
      positive predictive value of 85.71% (CI: 75.98% to 91.92%) compared to culture. We propose to
      evaluate this test for the diagnosis of melioidosis pneumonia in Myanmar.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2018</start_date>
  <completion_date type="Actual">April 4, 2019</completion_date>
  <primary_completion_date type="Actual">April 4, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a positive B.pseudomallei culture result</measure>
    <time_frame>January 2019</time_frame>
    <description>Number of patients with a positive sputum culture for B.pseudomallei expressed as a proportion of all patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1) Sensitivity, specificity, positive predictive value, negative predictive value of the RDT compared to culture</measure>
    <time_frame>January 2019</time_frame>
    <description>Using culture as the gold-standard the performance of the lateral flow assay will be assessed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients diagnosed with tuberculosis (TB) including multidrug resistant TB</measure>
    <time_frame>January 2019</time_frame>
    <description>Proportion of enrolled participants with a positive GeneXpert MTB/RIF test on sputum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients diagnosed with Influenza A/B</measure>
    <time_frame>March 2019</time_frame>
    <description>Proportion of enrolled participants with a positive Xpert Flu test on nasopharyngeal swab</description>
  </secondary_outcome>
  <enrollment type="Actual">300</enrollment>
  <condition>Melioidosis Pneumonia</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>InBios® Active Melioidosis DetectTM-Lateral Flow Assay</intervention_name>
    <description>Evaluation of a lateral flow assay for the detection of B.pseudomallei 6-deoxyheptan capsular polysaccharide antigen from sputum</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The population investigated will be patients attending two non-governmental organisation
        community clinics in the most deprived areas of Yangon, Myanmar
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt;18 years old

          2. Reported fever or axillary temperature &gt; 37.5 °C

          3. Productive cough

          4. Written informed consent

        Exclusion Criteria:

        1. Inability to provide a sputum specimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth A Ashley, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Myanmar Oxford Clinical Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Smithuis, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Myanmar Oxford Clinical Research Unit and Medical Action Myanmar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clare Warrell, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Myanmar Oxford Clinical Research Unit and Medical Action Myanmar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Dance, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ni Ni Tun, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Medical Action Myanmar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mo Mo Win, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Department of Medical Research, Myanmar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alistair McLean, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Myanmar Oxford Clinical Research Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyaw Soe</last_name>
    <role>Study Director</role>
    <affiliation>Myanmar Oxford Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Action Myanmar Clinics</name>
      <address>
        <city>Yangon</city>
        <country>Myanmar</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Myanmar</country>
  </location_countries>
  <reference>
    <citation>Limmathurotsakul D, Golding N, Dance DA, Messina JP, Pigott DM, Moyes CL, Rolim DB, Bertherat E, Day NP, Peacock SJ, Hay SI. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat Microbiol. 2016 Jan 11;1:15008. doi: 10.1038/nmicrobiol.2015.8.</citation>
    <PMID>27571754</PMID>
  </reference>
  <reference>
    <citation>Houghton RL, Reed DE, Hubbard MA, Dillon MJ, Chen H, Currie BJ, Mayo M, Sarovich DS, Theobald V, Limmathurotsakul D, Wongsuvan G, Chantratita N, Peacock SJ, Hoffmaster AR, Duval B, Brett PJ, Burtnick MN, Aucoin DP. Development of a prototype lateral flow immunoassay (LFI) for the rapid diagnosis of melioidosis. PLoS Negl Trop Dis. 2014 Mar 20;8(3):e2727. doi: 10.1371/journal.pntd.0002727. eCollection 2014 Mar.</citation>
    <PMID>24651568</PMID>
  </reference>
  <reference>
    <citation>Chierakul W, Wuthiekanun V, Chaowagul W, Amornchai P, Cheng AC, White NJ, Day NP, Peacock SJ. Short report: disease severity and outcome of melioidosis in HIV coinfected individuals. Am J Trop Med Hyg. 2005 Dec;73(6):1165-6.</citation>
    <PMID>16354832</PMID>
  </reference>
  <reference>
    <citation>Shaw T, Tellapragada C, Ke V, AuCoin DP, Mukhopadhyay C. Performance evaluation of Active Melioidosis Detect-Lateral Flow Assay (AMD-LFA) for diagnosis of melioidosis in endemic settings with limited resources. PLoS One. 2018 Mar 26;13(3):e0194595. doi: 10.1371/journal.pone.0194595. eCollection 2018.</citation>
    <PMID>29579128</PMID>
  </reference>
  <reference>
    <citation>Woods KL, Boutthasavong L, NicFhogartaigh C, Lee SJ, Davong V, AuCoin DP, Dance DAB. Evaluation of a Rapid Diagnostic Test for Detection of Burkholderia pseudomallei in the Lao People's Democratic Republic. J Clin Microbiol. 2018 Jun 25;56(7). pii: e02002-17. doi: 10.1128/JCM.02002-17. Print 2018 Jul.</citation>
    <PMID>29720430</PMID>
  </reference>
  <reference>
    <citation>Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med. 2012 Sep 13;367(11):1035-44. doi: 10.1056/NEJMra1204699. Review.</citation>
    <PMID>22970946</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pneumonia</keyword>
  <keyword>melioidosis</keyword>
  <keyword>Myanmar</keyword>
  <keyword>diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melioidosis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

